By this mechanism of action, Bexotegrast can be used for the reduction of systemic side effects and toxicities produced by the full TGF‐β signaling pathway inhibition in the treatment of IPF, as well as inhibiting the expression of mRNA collagen.85 This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.